Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087061 · ClinicalTrials.gov registry record · Phase 1
Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma
A Phase 1 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00087061 is a Phase 1 study that has completed, run by Jonsson Comprehensive Cancer Center.
The verdict
NCT00087061, a Phase 1 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gimatecan, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I/II trial is studying the side effects and best dose of gimatecan in treating patients with recurrent or progressive primary malignant glioma.
Interventions
- DRUG gimatecan
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-05 |
| Est. Completion | 2005-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087061
The ClinicalTrials.gov registry entry for NCT00087061 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which gimatecan is the first listed.
NCT00087061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087061 about?
NCT00087061 is a clinical study titled "Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma". RATIONALE: Drugs used in chemotherapy, such as gimatecan, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I/II trial is studying the side effects and best dose of gimatecan in treating patients with recurrent or progressive primary malignant...
What is the current status of trial NCT00087061?
This trial is currently completed. It is a Phase 1 study. The study started on 2004-05. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00087061?
The interventions under investigation include: gimatecan (DRUG).
Who is sponsoring clinical trial NCT00087061?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.